Results 191 to 200 of about 17,592 (206)

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

Annals of Oncology, 2021
MIGUEL Martin, C Zielinski, E M Ciruelos   +2 more
exaly  

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

Annals of Oncology, 2018
Paul Cottu, V D'Hondt, S Dureau
exaly  

Physiologically Based Pharmacokinetic Modeling of Palbociclib

Journal of Clinical Pharmacology, 2017
Yanke Yu, Cho-Ming Loi, Diane Wang
exaly  

Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6‐independent manner

Molecular Oncology, 2017
Feng-Shu Hsieh, Li-Ju Chen, Chung-Wai Shiau   +2 more
exaly  

P53 pathway is a major determinant in the radiosensitizing effect of Palbociclib: Implication in cancer therapy

Cancer Letters, 2019
Diego M Fernández-Aroca, Olga Roche, Sebastiã Sabater   +2 more
exaly  

Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial

Annals of Oncology, 2018
Luca Malorni, Giuseppe Curigliano, A M Minisini   +2 more
exaly  

Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis

European Journal of Cancer, 2017
J Raphaël, Joelle Helou, Kathleen I Pritchard   +2 more
exaly  

Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer

Breast Cancer Research and Treatment, 2020
Bahar Moftakhar, Manidhar Lekkala, Ajay Dhakal   +2 more
exaly  

Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia–mutated kinase–mediated DNA damage response

European Journal of Cancer, 2018
Chao-Yuan Huang, Feng-Shu Hsieh, Cheng-Yi Wang   +2 more
exaly  

Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies

European Journal of Cancer, 2018
Hope S Rugo, Richard S Finn, Nadia Harbeck   +2 more
exaly